2 results
Approved WMORecruiting
We will develop a bi-daily low-dose metronomic treatment schedule with paclitaxel in a convenient oral formulation and test whether this therapy has significant anti-angiogenic and anti-tumor activity.
Approved WMORecruiting
Primary- Continuation of treatment- SafetySecondairy- Documentation of tolerability